Organisation paid for research Program year 2023 Source: CMS Open Payments

Briggs Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$319,657

103 payments

Through program year 2023, Briggs Clinical Research LLC is reported as receiving $319,657 in research payments, across 103 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $4,437 1
2022 Research $12,511 9
2021 Research $65,870 33
2020 Research $28,984 18
2019 Research $207,854 42

Breakdown

Who paid Research payments · program years 2019–2023
  1. Novo Nordisk AS $177,967 22 payments
  2. CSL Behring $63,486 30 payments
  3. Kowa Research Institute, Inc. $24,267 22 payments
  4. Akebia Therapeutics Inc $19,417 15 payments
  5. Regeneron Pharmaceuticals, Inc. $13,839 4 payments
  6. AstraZeneca Pharmaceuticals LP $8,685 1 payment
  7. Sanofi US Services Inc. $8,116 8 payments
  8. Lexicon Pharmaceuticals, Inc. $3,880 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. Nn1250-4419 $106,799 12 payments
  2. A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease $63,486 30 payments
  3. Nn1250-4252 $52,807 5 payments
  4. Nn9535-4321 $18,360 5 payments
  5. K-877-302 $15,620 15 payments
  6. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis $13,839 4 payments
  7. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Conversion) $13,716 6 payments
  8. A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $8,685 1 payment
  9. K-877-302 $8,646 7 payments
  10. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function $4,922 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record